Lonza and California Peptide Research form strategic alliance

Lonza and California Peptide Research (CPRI) have entered into a strategic collaboration to offer a more effective service to customers requesting peptide manufacturing and development services.

Lonza and California Peptide Research (CPRI) have entered into a strategic collaboration to offer a more effective service to customers requesting peptide manufacturing and development services.

CPRI’s high-quality small-scale services complement Lonza's extensive capabilities in custom cGMP peptide manufacturing and development. With proximity to a core customer base in the North American pharmaceutical market, CPRI adds geographic diversity to Lonza's existing facilities in Braine-l'Alleud (Belgium), Visp (Switzerland), Nansha (China), and Kouřim (Czech Republic). CPRI’s offering includes milligram- to multi-gram-scale custom synthesis and a wide variety of catalogue products, as well as consulting services and technical support.

The alliance will provide customers with a more complete peptide offering – from research through commercial supply – and enable a seamless transition of custom peptide projects between CPRI’s small-scale facility and Lonza’s